Clinical Trial Update: A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer [Phase 1]

View source ↗

Summary

An early-phase study evaluating H3B-6545 in combination with palbociclib for advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• H3B-6545
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Eisai Inc. | Conditions: Receptors, Estrogen, Genes, Erbb-2 | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-22